



The Place of Radiotherapy in the Management of Desmoid Tumors

Fatma Elloumi¹, Fatma Ajengui¹, Lilia Ghorbal^{1*}, Mayada Bourmeche¹
and Jamel Daoud¹

¹Department of Radiation Oncology, Habib Bourguiba University Hospital, Sfax, Tunisia.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

Editor(s):

(1) Dr. Krishnangshu Bhanja Choudhury, R. G. Kar Medical College and Hospital, India.

Reviewers:

(1) Shalini Gupta, King George's Medical University, India.

(2) Linwei Wang, Wuhan University, China.

Complete Peer review History: <https://www.sdiarticle4.com/review-history/73031>

Mini-Review Article

Received 25 June 2021
Accepted 31 August 2021
Published 03 September 2021

ABSTRACT

The management of desmoid tumors has undergone changes in recent years including active surveillance for asymptomatic and non-progressive tumors. The place of radiotherapy is contested due to significant toxicity. Radiation therapy is offered as an alternative to surgery for tumors that are unresectable or whose removal exposes functional or life damage.

In view of the high recurrence potential, radiotherapy should also be discussed after surgery for desmoid tumors. Irradiation has shown its benefit in terms of local control for tumors whose excision is incomplete. Its place after full surgery is controversial.

Through this review of the literature, we propose to support the indications for radiotherapy in the management of desmoid tumors and to present its technical aspects.

Keywords: Desmoid; tumor; treatment.

1. INTRODUCTION

Desmoid tumors are monoclonal proliferations of fibroblasts and myofibroblasts belonging

to soft tissue tumors. They are rare and originate from mesenchymal stem cells. They can be sporadic or hereditary [1].

*Corresponding author: E-mail: lilia.ghorbal@yahoo.fr;

Their etiopathogenesis remains poorly understood, involving a traumatic cause and genetic and hormonal factors [2,3]. The β catenin is considered a diagnostic, prognostic and therapeutic biomarker [3]. Desmoid tumors are distributed according to site into intra-abdominal and extra-abdominal tumors including tumors of the abdominal wall [2,4], considered benign, do not give secondary locations but have a significant local and locoregional destructive power associated with a significant risk of local relapse after treatment.

Their evolution is unpredictable with phases of stabilization, regression and scalability. As a result, the management of these tumors remains non-standardized [2].

Locoregional treatment should be considered for progressive tumors. Surgery was for a long time the first-line treatment for resectable tumors.

Treatment strategies have recently changed with the adoption of a new attitude of active surveillance recommended for non-progressive tumors in asymptomatic patients [4].

Radiotherapy appears to provide a benefit for unresectable tumors or insufficient excision. Its place is controversial given the lack of a high level of scientific evidence and significant toxicity.

In this review of the literature, we are interested in supporting the indications for radiotherapy in the management of desmoid tumors of the abdominal and extra-abdominal wall.

2. PLACE OF EXCLUSIVE RADIOTHERAPY

In the majority of cases, the therapeutic sequence for desmoid tumors included surgical excision. Surgery with healthy margins is the treatment of choice, offering a 5-year local control rate ranging from 72% to 78% depending on the series [4-6] (Table 1).

Due to extensive tumor extension, macroscopically complete surgery is often either impossible or unacceptable, exposing major functional complications or cosmetic damage [7]. R0 excision was only possible in 58% of patients in the meta-analysis published by Janssen et al in 2017 on 1005 patients [4]. The sequelae of surgery should be considered in young patients

of median age varying between 28 and 35 years [5,8].

In fact, complications such as amputations and disability are reported in 4% of operated patients [6].

Exclusive radiotherapy has emerged as an alternative to surgery, but its place remains poorly established given the lack of randomized trials comparing the two treatment modalities.

An early study published in 1993, involving 40 patients, reported a risk of progression after surgery of 29%. This rate was higher compared to that after radiotherapy, estimated at 19% [9].

Keus et al, in a prospective phase II study of the EORTC concerning 44 patients, showed a local control rate at 3 years of 81.5% after exclusive radiotherapy with stabilization of the disease in 41% of cases and a response complete in 13.6% of patients [10].

A comparative review of 22 articles, grouping together 780 patients and excluding abdominal and head and neck tumors, reported local control rates at 3 years by radiotherapy alone of 83 and 73% respectively for primary and recurrent tumors versus 78% and 79% by a combination of surgery and radiotherapy [6].

The local control rate at 4 years was 78% in a recently published retrospective study involving 50 patients, half of whom received radiotherapy alone. This rate was comparable to surgical results [5].

Bishop et al, in a series of 209 patients treated with radiotherapy alone, reported local control rates at 5 years and 10 years of 64 and 61%, respectively, which were significantly lower compared to combined treatment. In multivariate analysis, an age less than 30 years and a tumor size greater than 10 cm are associated with a greater risk of relapse.

Patients under 30 years of age had a local control rate at 3 years of 43% compared to 75% for patients over 30 years [11]. This finding was also reported in other series with cut-off ages varying between 20 and 40 years. The authors suggested the hypothesis of an intricate radioresistance to a genetic predisposition in young patients [11-15].

The role of exclusive radiotherapy for recurrent tumors was also studied by Nuyttens et al. [6] who reported a local control rate at 3 years of 73% for recurrences treated with exclusive radiotherapy. This rate was higher compared to treatment of relapses by surgery alone.

Although there is no direct comparison between the two treatment modalities, the local control rates reported in the series of exclusive radiotherapy were not inferior to the results of the surgical series (11, 12). Many authors recommend radiotherapy as an alternative to surgical treatment for locally advanced tumors whose removal would be responsible for significant damage [5,11,13,14,16,17].

3. PLACE OF ADJUVANT RADIOTHERAPY

Combined treatment with surgery and radiotherapy was the most common treatment approach to resectable desmoid tumors.

According to the review by Nuyttens et al of 780 patients, excluding abdominal, head and neck locations, this combination offers a better rate of local control at 3 years in the event of R1 excision compared to surgery alone. This rate increases from 41% to 75% in the case of combined treatment (p = 4.10-10) (Table 2).

In fact, the authors reported a significant gain in local control at 3 years by the combination of

radiosurgery versus exclusive surgery, even in the event of complete R0 type excision (94% versus 72% with p = 0.0048). This gain was found for both primary and recurrent tumors [6] (Table 3).

These results were also supported by the review published by Janssen et al in 2017 about 1295 patients of which 1005 had surgery alone and 290 patients had adjuvant radiotherapy. The combined treatment was superior to excision alone with a statistically significant difference in terms of local control.

This gain was significant for both primary tumors and recurrent tumors in the event of insufficient excision. In contrast, surgery alone was better than a combination of radiotherapy with full R0 surgery [4] (Table 4).

However, excess with positive margins was not associated with an increased risk of recurrence in a surgical series by Lev et al in 189 patients treated with surgery and / or radiotherapy [18]. Some authors recommend close monitoring in the event of incomplete resection without recourse to adjuvant radiotherapy, which will only be initiated in the event of symptomatic progression and after discussion in a multidisciplinary team [5,7,16,17].

Table 3 Local Control for Free Margins, Positive Margins, or Unknown Margins Treated with Surgery Alone, Surgery with Radiotherapy, or Radiotherapy Alon.

Table 1. Results of exclusive radiotherapy

	Number	Median follow-up	Mean dose of radiotherapy	Results
J C Acker et al. [9]	40	57.5	54	19% Progression after radiotherapy Vs 29% after surgery
Keus et al. [10]	44	57.6	54	- Local control rate at 3 years 81.5 - Stabilization of the disease: 41% - A complete answer: 13.6%
J J Nuyttens et al. [6]	780	56.2	52.8	Local control rate at 3 years: - Abdominal tumors 83% - Head and neck tumors 73%
A M Hong et al. [5]	50	51	50.4	Local control rate at 4 years: 78%
Bishop et al. [11]	209	98	50.6	Local control rate : - at 5 years 64% - at 10 years 61%

Table 2. Local control for free margin and positive margin treated with surgery alone or surgery with radiotherapy

	Surgery alone		Surgery + Radiotherapy
	%	%	P value
Free margin	72	94	0.0048
Positive margins	41	75	4 × 10 ⁻¹⁰
			4 × 10 ⁻¹⁰
			4 × 10 ⁻¹⁰
			4 × 10 ⁻¹⁰
Total	61	75	0.0002

P value in comparison with surgery alone

Table 3. Local control after treatment of primary, recurrent tumor

	Surgery alone		Surgery + Radiotherapy
	%	%	P value
Primary tumor	62	78	0.027
Recurrence	47	79	4 × 10 ⁻¹⁰
			4 × 10 ⁻¹⁰
			4 × 10 ⁻¹⁰
			2 × 10 ⁻⁵

P value in comparison with surgery alone

Table 4. Summary of treatment outcomes for surgery and surgery with adjuvant radiotherapy according to surgical margin according to the janssen study

Margin	Referral status	Recurrence rate	
		Surgery	Surgery+radiotherapy
R0	Primary	15.2 %	22 %
	Recurrent	36 %	29 %
R1	Primary	29 %	23.8 %
	Recurrent	73 %	38 %
R2	Primary	64 %	21 %
	Recurrent	100 %	56 %
Total	Primary	25.6 %	22.7 %
	Recurrent	52.7 %	36 %

4. TECHNICAL ASPECTS OF RADIOOTHERAPY

The dose prescribed in the different studies varied between 30 and 75 Gy. A comparison of local relapse rates according to dose levels showed that a dose above 50 Gy significantly improves local control [6].

On the other hand, a dose escalation beyond 56 Gy was associated with a significant increase in toxicity in a study involving 115 patients treated with exclusive or adjuvant radiotherapy [11].

Irradiation according to IMRT and VMAT techniques has been compared to 3D irradiation in patients treated for desmoid tumors of the

chest wall. New techniques offer better dose distribution with reduced dose to healthy organs [19].

CTV should encompass the surgical bed in case of adjuvant radiotherapy. When radiotherapy is the primary treatment, GTV should include all the tumor. Margins are added to GTV to obtain CTV.

5. THE TOXICITY OF RADIOOTHERAPY

The evaluation of the results of radiotherapy necessarily involves an evaluation of post-radiation toxicity. Late toxicity such as edema, paresthesia, stiffness and weakness is described in 36% of the cases of the radiotherapy series against 20% in the surgical series [20].

Skin toxicity was the most represented in the different series. It was like lymphedema in 20% of cases and fibrosis in 6 to 9% of cases [6,10].

Radiation-induced cancers were reported in 0.7% of patients in the meta-analysis published in 2000 about 780 patients and in 2% of cases in a series of 115 patients, 34 of whom received a dose greater than 56 Gy (6 and 13). Di Marco et al report a case of radiation-induced pleomorphic cell sarcoma 21 years after re-irradiation of a recurrent desmoid tumor in the pelvic region [21].

6. CONCLUSION

Although the rates of local control after radiotherapy for desmoid tumors are satisfactory, the place of irradiation alone or in combination with surgery remains controversial. It is recommended for advanced tumors where excision is impossible or mutilating. Its place after surgery is questionable given its non-trivial toxicity.

Despite the rarity of this entity, it is imperative to optimize its management through randomized trials comparing the different treatment modalities.

CONSENT

As per international standard or university standard, Participants' written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL

As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Alman BA, Pajerski ME, Diaz-Cano S, Corboy K, Wolfe HJ. Aggressive fibromatosis (Desmoidtumor) is a monoclonal disorder. *Diagn Mol Pathol*. 1997;6:98-101.
2. Montagliani L, Duverger V. Desmoid tumors. *Journal of Surgery*. 2008;145(1): 20-26.
3. Salas S, Chibon F. Biology and signaling pathways involved in the oncogenesis of desmoid tumors. *Cancer Bulletin*. 2020; 107(3):346-351.
4. Janssen ML, van Broekhoven DL, Cates JM, Bramer WM, Nuyttens JJ, Gronchi A, et al. Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis. *Br J Surg*. 2017;104(4):347e357.
5. Hong AM, Jones D, Boyle R, Stalley P. Radiation therapy as an alternative treatment for desmoid fibromatosis. *Clinical Oncology*. 2018;1-4.
6. Nuyttens JJ, Rust PF, Thomas CR Jr, et al. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles. *Cancer*. 2000;88:1517-1523.
7. Bonvalot S, Rimareix F, Paumier A, Roberti E, Bouzaiene H, Le Pécoux C. What is new in the local approach of limb sarcomas and desmoid tumours?. *Cancer Radiother*. 2010;14:455-9.
8. Cotte E, Glehen O, Monneuse O, Cotton F, Vignal J. Desmoid tumors associated with familial adenomatous polyposis. *Gastroenterol Clin Biol*. 2004;28:574-581.
9. Acker JC, Bossen EH, Halperin EC. The management of desmoids Tumors. *Int J Radiat Oncol Biol Phys*. 1993;26:851-8.
10. Keus RB, Nout RA, Blay JY, de Jong JM, Hennig I, Saran F, et al. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis e an EORTC STBSG and ROG study (EORTC 62991-22998). *Ann Oncol*. 2013;24(10):2672e2676.
11. Long- term outcomes for patients with desmoid fibromatosis treated with radiation Therapy: A 10-Year Update and Re-evaluation of the Role of Radiation Therapy for Younger Patients. Andrew J Bishop, Maria A Zarzour, Ravin Ratan, Keila E Torres, Barry W Feig, Wei-Lien Wang, et al. *Int J Radiation Oncol Biol Phys*. 2019;XX:1-8.
12. Tsagozis P, Stevenson JD, Grimer R, et al. Outcome of surgery for primary and recurrent desmoid-type fibromatosis. A retrospective case series of 174 patients. *Ann Med Surg (Lond)*. 2017;17:14-19.
13. Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoids tumors treated with radiation therapy. *Int J Radiat Oncol Biol Phys*. 2008;71:41-447.
14. Bates JE, Morris CG, Iovino NM, et al. Radiation therapy for aggressive

- fibromatosis: The association between local control and age. *Int Radiat Oncol Biol Phys.* 2018;100:997-1003.
15. Wirth L, Klein A, Baur-Melnyk A, et al. Desmoid tumors of the extremity and trunk. A retrospective study of 44 patients. *BMC Musculoskelet Disord.* 2018; 19:2.
 16. Kasper B, Baumgarten C, Bonvalot S, et al. On behalf of the desmoidworking group. Management of sporadicdesmoid-type fibromatosis: A European consensus approachbased on patients and professionals expertise - a sarcoma patients EuroNet (SPAEN) and European organization for research and treatment of cancer (EORTC) / Soft tissue and Bone sarcoma group (STBSG) initiative. *J Cancer.* 2015;51:127-136
 17. Kasper B, Baumgarten C, Garcia J, et al. On behalf of the desmoids working group. An update on the management of sporadic desmoid-type fibromatosis: A European consensus initiative between sarcoma patients EuroNet (SPAEN) and European organization for research and treatment of cancer (EORTC) / Soft tissue and Bone sarcoma group (STBSG). *Ann Oncol.* 2017;28:2399-2408.
 18. Lev D, Kotilingam D, Wei C, Ballo MT, Zagars GK, Pisters PW, et al. Optimizing treatment of desmoid tumors. *J Clin Oncol.* 2007;25(13):1785-91.
 19. Liu J, Ng D, Lee J, Stalley P, Hong A. Chest wall desmoid tumors treated with definitive radiotherapy: A plan comparison of 3D conformal radiotherapy, intensity-modulated radiotherapy and volumetric-modulated arc radiotherapy. *Radiat Oncol.* 2016;11:34.
 20. Goy BW, Lee SP, Eilber F, Dorey F, Eckardt J, Fu Y, et al. The Role of adjuvant radiotherapy in the treatment of resectable desmoid tumors. *Int J Radiat Oncol Biol Phys.* 1997;39:659–65.
 21. Radiation-induced undifferentiated pleomorphic sarcoma after radiation therapy for a desmoid tumor. J Di Marco, R Kaci, B Orzel, R. Nizard, J-D Laredo. *Cancer / Radiotherapy.* 20(1):36-38.

© 2021 Elloumi et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

*The peer review history for this paper can be accessed here:
<https://www.sdiarticle4.com/review-history/73031>*